Stapedectomy — Surgical Treatment for Otosclerosis and Conductive Hearing Loss — Cost, Top Hospitals & Success Rates | MyMedicPlus

Stapedectomy is a microsurgical procedure in which the stapes — the innermost and smallest of the three ossicles (hearing bones) in the middle ear — is entirely removed and replaced with a prosthetic device (piston) to restore sound conduction from the tympanic membrane to the inner ear. It is the definitive surgical treatment for otosclerosis, a condition in which abnormal spongy bone growth immobilises the stapes footplate in the oval window, progressively impairing sound transmission and causing conductive hearing loss.

Otosclerosis affects approximately 0.3–0.5% of the white population, is bilateral in 70% of cases, and predominantly affects women in the third and fourth decades of life. The disease is autosomal dominant with incomplete penetrance (~25%). Beyond conductive hearing loss, cochlear otosclerosis can extend to the spiral ligament and cochlea, causing additional sensorineural hearing loss that is not corrected by surgery.

The procedure was pioneered by Julius Lempert (fenestration technique, 1938) and refined by John Shea Jr., who performed the first successful stapedectomy with a Teflon-wire prosthesis and vein graft in 1956. The technique evolved from total footplate removal (classic stapedectomy) to small-fenestra stapedotomy (creating a 0.6-mm hole in the footplate rather than removing it), which is now the preferred modern technique. However, classic stapedectomy remains in the surgical armamentarium for obliterative otosclerosis and for surgeons who prefer it.

When successful, stapedectomy is one of the most gratifying operations in otolaryngology, producing immediate and dramatic hearing improvement that can persist for decades. Careful patient selection, meticulous surgical technique, and appropriate prosthesis selection are the determinants of outcome.

Stapedectomy is primarily indicated for the following conditions:

• Clinical otosclerosis (fenestral): The classic indication. Abnormal spongy bone fixates the stapes at the oval window niche, producing a progressive conductive hearing loss with a characteristic Carhart notch (dip at 2 kHz on bone conduction audiogram). The Schwartze sign — reddish hue through the tympanic membrane from increased vascularity over the promontory — may be present.
• Obliterative otosclerosis: Advanced disease in which the entire footplate is replaced by thick, vascular, spongiotic bone — classified as biscuit footplate, obliterative, or floating after drilling. Obliterative disease is surgically more challenging and is associated with higher risk of perilymph gusher and sensorineural hearing loss. It has been linked to mutations in the NF2 gene in some studies.
• Osteogenesis imperfecta (Van der Hoeve syndrome): The triad of blue sclerae, brittle bones, and stapes fixation. Stapedectomy can improve hearing but carries higher risk due to the fragility of the ossicular chain and increased perilymph gusher risk. Bisphosphonate therapy may be used pre-operatively to stabilise bone metabolism.
• Post-traumatic stapes fixation: Rare; may result from temporal bone fracture or surgical trauma. Stapedectomy or stapedotomy can restore hearing if the cochlea is undamaged.
• Tympanosclerosis involving the footplate: Calcified plaques fixing the stapes; surgical mobilisation or replacement may be required. Outcomes are less predictable than for classic otosclerosis.

Note: stapedectomy does not address the sensorineural component of cochlear otosclerosis; cochlear fluoride therapy (sodium fluoride 20–40 mg/day) is sometimes prescribed to retard cochlear disease progression, though evidence remains controversial.

Patient selection is critical to optimising outcomes and avoiding complications:

• Audiometric criteria: An air-bone gap (ABG) of ≥30 dB on pure tone audiometry, demonstrating significant conductive hearing loss amenable to surgical correction. The better-hearing ear may be operated first (though some surgeons prefer the worse ear), as a precaution against the 1–2% risk of profound sensorineural hearing loss from the procedure.
• Cochlear reserve: Bone conduction thresholds ≤35 dB HL in the speech frequencies (500–3,000 Hz) indicate sufficient sensorineural reserve that the restored sound conduction will yield meaningful hearing improvement. Severely impaired bone conduction suggests cochlear otosclerosis that will limit post-operative aided or unaided hearing.
• Single functioning ear: Stapedectomy in the only hearing ear is highly controversial; the risk of total deafness (1–2%) must be weighed extremely carefully. Many surgeons defer or refuse surgery in this situation, preferring hearing aids or osseointegrated bone-anchored hearing devices (BAHA).
• Middle ear status: Active otitis media, tympanic membrane perforation, or Eustachian tube dysfunction must be treated before stapes surgery. An inactive, well-healed tympanic membrane and healthy middle ear mucosa are prerequisites.
• Age considerations: There is no absolute age limit. However, children with otosclerosis are rare, and surgery in active disease (positive Schwartze sign) carries higher risk of sensorineural hearing loss. Elderly patients with comorbidities may prefer hearing aids over surgical risk.
• Pregnancy: Otosclerosis frequently worsens during pregnancy due to oestrogen effects. Surgery is generally deferred until after delivery and cessation of breastfeeding.

Stapedectomy is performed under the operating microscope through a transcanal approach (endaural or postauricular incisions are rarely needed):

• Anaesthesia: Local anaesthesia with intravenous sedation is preferred in many centres, as it allows intra-operative hearing testing (patient reports improvement when the prosthesis is placed). General anaesthesia is used in anxious patients, children, or when technical difficulty is anticipated.
• Footplate management (classic stapedectomy): After division of the stapedius tendon and incudostapedial joint and fracture of the posterior crus, the stapes superstructure is removed. The footplate is then removed in toto using footplate hooks, microforceps, or a hand drill — producing a large oval window opening that must be sealed before prosthesis placement.
• Tissue seal: The exposed perilymph-filled oval window must be sealed to prevent perilymph fistula and to support the prosthesis. The three main seal materials are: fat graft (taken from the earlobe — most haemostatic, provides cushioning), perichondrium (from the tragus — firm and durable), and vein graft (from the hand dorsum — flexible and conformable). Each has proponents; outcomes are comparable between seal types.
• Prosthesis types: The piston is positioned with its hook looped over the long process of the incus and its footplate end resting in/through the oval window opening or seal tissue. Common prostheses include: House piston (stainless steel wire + Teflon); Robinson prosthesis (stainless steel bucket-handle design); Causse prosthesis (fluoroplastic, total ossicular replacement variant); and modern Nitinol memory-metal pistons that self-crimp onto the incus process when warmed to body temperature, eliminating the need for crimping forceps.
• MRI compatibility: Most modern stainless steel and titanium pistons are MRI-conditional (safe at 1.5T and 3T); patients should carry their implant card and inform radiographers before MRI scanning.

Stapedectomy, when successful, produces one of the most dramatic hearing improvements of any surgical procedure:

• Air-bone gap closure: The primary outcome measure is closure of the pre-operative ABG. Published series consistently report ABG closure to ≤10 dB in 60–70% of patients, and to ≤20 dB in 85–90% of patients — representing restoration of near-normal hearing in most cases. Chole and Brackmann established audiometric criteria widely used for reporting stapedectomy outcomes.
• Immediate improvement: Many patients notice dramatic hearing improvement within hours of surgery, even before the ear canal packing is removed. This is particularly gratifying for patients with severe social impairment from hearing loss.
• Durability: Hearing improvement is durable for decades in most patients. Studies with 10–20 years of follow-up demonstrate maintained hearing in 80–90% of cases, though slow revision rates (10–15% at 20 years) reflect late prosthesis displacement, necrosis of the incus long process, or progression of cochlear otosclerosis.
• Bilateral disease: For bilateral otosclerosis, the poorer-hearing ear is typically operated first to minimise binaural risk. The second ear may be operated after 6–12 months if the first is successful. Bilateral stapedectomy eliminates or greatly reduces hearing aid dependence in most patients.
• Tinnitus improvement: Many patients with pre-operative tinnitus report reduction or resolution after successful stapedectomy, though tinnitus persists in some and paradoxically worsens in rare cases.
• Social and professional rehabilitation: Restoration of hearing dramatically improves communication ability, social confidence, and professional function — with measurable improvements in quality of life scores (Glasgow Benefit Inventory, APHAB questionnaire).

Stapedectomy carries a small but important risk of serious complications that must be discussed thoroughly during consent:

• Sensorineural hearing loss (SNHL): The most feared complication. Mild-to-moderate SNHL occurs in approximately 3–5% of cases; profound or total SNHL (>80 dB) occurs in 1–2%. Causes include mechanical trauma to the membranous labyrinth, perilymph gusher with subsequent fibrous obliteration, or acoustic/thermal injury during drilling. Profound SNHL may necessitate cochlear implantation if bilateral.
• Perilymph gusher: Abnormally high perilymph pressure results in gushing of perilymph through the oval window at the time of footplate removal. Risk factors include X-linked stapes gusher (DFNX2/POU3F4 mutation — males with stapes fixation, dilated internal auditory canals on CT, and profound SNHL risk); anomalous inner ear anatomy; and Mondini malformation. Management involves immediate sealing with a fat graft and gentle suction; SNHL occurs in 50–70% of X-linked gusher cases.
• Floating footplate: The footplate sinks into the vestibule during attempted removal, potentially causing severe SNHL. This is more common with obliterative otosclerosis. The preferred response is to leave the sunken footplate and convert to a total footplate removal or stapedotomy approach.
• Taste disturbance and dry mouth: The chorda tympani nerve (taste to anterior two-thirds of tongue) traverses the middle ear and is often stretched or sacrificed during stapes surgery. Transient taste disturbance occurs in 20–30% of patients; permanent alteration in 5–10%.
• Vertigo and imbalance: Transient vertigo for 24–48 hours post-operatively is common. Persistent vertigo may indicate perilymph fistula or labyrinthine disruption.
• Facial nerve injury: The facial nerve occasionally takes an aberrant course over the oval window niche, with dehiscent bony covering. Injury is rare (<0.1%) with an experienced surgeon but can cause facial paralysis.
• Reparative granuloma: Foreign body reaction to the prosthesis or seal tissue, presenting with progressive hearing loss and tinnitus 4–6 weeks post-operatively; managed with corticosteroids or exploration.

Post-operative care and follow-up are essential for ensuring optimal healing and identifying complications early:

• Immediate post-operative: Bed rest for 24 hours with the operated ear uppermost. Patients are cautioned against nose-blowing, straining, and heavy lifting for 3 weeks to prevent Valsalva-induced perilymph fistula. Gelfoam packing in the ear canal is removed at 7–10 days.
• Water precautions: The ear must be kept dry for a minimum of 6 weeks. Swimming is avoided for 3 months. Hair-washing requires cotton wool and petroleum jelly to prevent water ingress via the ear canal.
• Audiometric follow-up: A formal pure tone audiogram with air and bone conduction is performed at 6–8 weeks post-operatively, when middle ear healing is complete and oedema has resolved. This establishes the baseline post-operative hearing level against which future changes are measured.
• Air travel: Avoided for at least 4–6 weeks. Eustachian tube equilibration pressure changes with altitude changes can stress the new oval window seal. Thereafter, the Valsalva manoeuvre should be performed gently.
• Long-term follow-up: Annual audiometric review for the first 5 years, then every 2–3 years. Late hearing deterioration may signal incus long-process necrosis (incudostapedial absorption due to avascular necrosis), prosthesis displacement, or cochlear otosclerosis progression — each requiring different management.
• Revision surgery: Approximately 5–10% of patients require revision stapedectomy, most commonly for displaced prosthesis or incus necrosis. Revision surgery carries a higher SNHL risk (5–10%) than primary surgery and should only be performed by experienced stapes surgeons.

The cost of stapedectomy varies by country, institution, prosthesis type, and anaesthesia method:

• Procedure complexity: Primary stapedectomy in a straightforward case (normal anatomy, good cochlear reserve) is less expensive than revision surgery, bilateral sequential stapedectomy, or surgery for obliterative otosclerosis requiring drilling.
• Prosthesis cost: Basic Teflon-wire pistons are inexpensive (USD 20–50). Specialised prostheses — Nitinol self-crimping pistons, TORP/PORP variants, or titanium — cost USD 200–800. In price-sensitive healthcare systems, basic prostheses achieve equivalent outcomes.
• Country costs: India (Apollo, Fortis, AIIMS): INR 40,000–1,20,000 (USD 480–1,440). UK (NHS): Free with referral; private: GBP 3,000–5,500. USA: USD 7,000–15,000 (including anaesthesia and day-surgery facility fee). Germany: EUR 5,000–9,000. India's accredited tertiary ENT centres offer world-class stapes surgery at a fraction of Western costs, attracting significant medical tourism.
• Anaesthesia: Local anaesthesia with sedation (preferred in many centres) is less expensive than general anaesthesia. When performed as a day-case procedure, hospital facility costs are substantially lower than overnight admission.
• Hearing aids as an alternative: For patients who decline surgery or are poor surgical candidates, modern hearing aids (behind-the-ear, receiver-in-canal, or bone-anchored) cost USD 1,000–4,000 per device and require ongoing maintenance and periodic replacement — with cumulative lifetime costs potentially exceeding surgery.

Several alternatives to stapedectomy exist for managing otosclerosis-related hearing loss:

• Stapedotomy (preferred modern technique): Rather than removing the entire footplate, a small hole (0.4–0.8 mm, typically 0.6 mm) is created in the footplate with a microdrill or laser, through which a thin piston prosthesis is inserted. This small-fenestra technique preserves the integrity of the bony labyrinthine capsule, reduces perilymph gusher risk, and minimises inner ear trauma. Modern literature increasingly favours stapedotomy over stapedectomy, with equivalent or superior audiometric outcomes and lower SNHL rates. Many surgeons now perform stapedotomy as their primary technique for all cases, reserving total footplate removal for obliterative disease only.
• Conventional hearing aids: Appropriately fitted behind-the-ear or in-the-canal hearing aids effectively amplify sound for conductive hearing loss. They are non-invasive, reversible, and risk-free — making them appropriate for patients who are not surgical candidates, have a single functioning ear, or who prefer to avoid surgery. Modern digital hearing aids with directional microphones, Bluetooth connectivity, and rechargeable batteries offer significant quality-of-life improvements.
• Bone-anchored hearing aids (BAHA): A titanium implant osseointegrated in the mastoid transmits sound directly via bone conduction to the cochlea, bypassing the dysfunctional ossicular chain. The Cochlear Baha, Oticon Medical Ponto, and MED-EL Osia systems are used for bilateral conductive hearing loss, single-sided deafness, or when conventional hearing aids are poorly tolerated. A BAHA on a soft band can be trialled non-invasively before surgical implantation.
• Sodium fluoride therapy: Oral sodium fluoride (20–40 mg/day) — or more recently, biphosphonates (alendronate) — has been used to retard progression of cochlear otosclerosis by inhibiting bone remodelling. Evidence for its efficacy in improving or stabilising sensorineural hearing is controversial and the treatment is not universally accepted; it does not address the mechanical fixation of the stapes and thus has no role in reversing conductive hearing loss.
• Cochlear implantation: Appropriate for end-stage bilateral cochlear otosclerosis with profound sensorineural hearing loss beyond the benefit of conventional amplification. Otosclerotic cochlear obliteration (labyrinthal ossification) may complicate electrode insertion; pre-operative CT is essential. Results are generally good, with word recognition scores superior to those achievable with hearing aids in severe-profound loss.